A

argenx

Develops antibody-based therapies for autoimmune diseases

CMC Development Lead

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeGhent, BelgiumIn-person

About the Job

Requirements

  • An advanced degree in life sciences is required; a Master's degree is acceptable and a PhD is preferred.
  • A postgraduate degree in business administration is required.
  • A minimum of 10 years of CMC experience in drug substance and/or drug product manufacturing is required.

Responsibilities

  • Build the CMC Development plan with the CMC Development team, ensuring alignment with the clinical development plan and clinical trial supply strategy.
  • Define the long-term CMC strategy for specific assets or projects in line with the Target Product Profile.
  • Provide leadership and facilitate communication between the Asset Strategy Team or project team and the CMC team.
  • Develop the scientific CMC strategy, including regulatory strategy, manufacturing process, formulation, and presentation development, and translate it into a CMC project plan with support from the CMC project manager for one or more drug development programs or projects.
  • Lead the CMC Development team for assigned projects or assets, maintain end-to-end oversight, and act as the CMC representative for all TechOps activities, including drug substance, drug product, analytical, supply, and CMC regulatory activities.
  • Actively participate in Asset Strategy Team discussions and overall development discussions.
  • Ensure proactive two-way communication with relevant stakeholders, including the CMC Development team, Clinical Trial Supply, Asset Asset Strategy Team, and Integrated Development Teams.
  • Prepare and present strategic CMC discussions for endorsement at CMC or Asset Strategy Team governance bodies.
  • Collaborate with cross-functional teams to evaluate external assets and ensure alignment with internal development strategies and standards.
  • Support, coordinate, and conduct due diligence activities for potential new external programs, including assessment of CMC risks, opportunities, and integration requirements.

Desired Qualifications

  • A PhD in life sciences is preferred.

About the Company

argenx

Develops antibody-based therapies for autoimmune diseases

Argenx develops and markets antibody-based therapies for severe autoimmune diseases, turning immunology research into medicines. Its lead drug, efgartigimod (VYVGART), and the subcutaneous VYVGART Hytrulo treat conditions like generalized myasthenia gravis and CIDP by modulating the immune system through FcRn pathways. The company differentiates itself with antibody engineering and a co-creation model with academic and industry partners, plus a pipeline targeting FcRn-, complement-, and other autoimmune pathways and a global development footprint. Its goal is to provide effective antibody medicines for autoimmune diseases and broaden global patient access.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Amsterdam, Netherlands
Founded
2008

Recently Posted Jobs

Explore more opportunities at argenx

See more jobs